...
首页> 外文期刊>BMC Nephrology >High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats
【24h】

High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats

机译:正常和尿毒症大鼠的高剂量静脉铁,矿物质稳态和完整FGF23

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background High iron load might have a number of toxic effects in the organism. Recently intravenous (iv) iron has been proposed to induce elevation of fibroblast growth factor 23 (FGF23), hypophosphatemia and osteomalacia in iron deficient subjects. High levels of FGF23 are associated with increased mortality in the chronic kidney disease (CKD) population. CKD patients are often treated with iv iron therapy in order to maintain iron stores and erythropoietin responsiveness, also in the case of not being iron depleted. Therefore, the effect of a single high iv dose of two different iron preparations, iron isomaltoside 1000 (IIM) and ferric carboxymaltose (FCM), on plasma levels of FGF23 and phosphate was examined in normal and uremic iron repleted rats.
机译:背景高铁负荷可能对生物体产生许多毒性作用。最近,已经建议在铁缺乏的受试者中静脉内(iv)铁诱导成纤维细胞生长因子23(FGF23),低磷血症和骨软化症的升高。 FGF23的高水平与慢性肾脏病(CKD)人群的死亡率增加有关。 CKD患者经常接受静脉铁剂治疗,以维持铁存储和促红细胞生成素的反应性,即使在不消耗铁的情况下也是如此。因此,在正常和尿毒症补充铁的大鼠中检查了单一高静脉注射剂量的两种不同铁制剂(异麦芽糖苷铁1000(IIM)和羧基麦芽糖铁(FCM))对FGF23和磷酸盐血浆水平的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号